City Therapeutics, a clinical-stage biotechnology company developing RNA interference (RNAi) therapies, priced its upsized initial public offering at $18.00 per share. The company is selling 11,111,111 shares, which should raise about $200 million before fees and expenses. Shares are expected to begin trading on the Nasdaq Global Market on October 16, 2026, under the ticker "CTY." The offering should close on October 19, 2026. Underwriters have a 30-day option to buy up to 1,666,666 more shares. Goldman Sachs, Jefferies, Stifel, and Oppenheimer are joint book-running managers. The Cambridge, Massachusetts company's lead programmes target thromboembolic diseases, Stargardt disease and other retinal diseases, and anaemia linked to chronic diseases.

City Therapeutics files to take its RNAi platform public. City Therapeutics, an RNAi drug developer counting Fidelity among its backers, has filed for a U.S. listing - a test of whether the biotech IPO window is genuinely open again. City Therapeutics Inc., an RNA interference drug developer backed by Fidelity, filed for a U.S. initial public offering on Sept. 24, 2026, seeking additional funding for medicines that work by silencing disease-related proteins. City Therapeutics Inc. has filed for an initial public offering in the United States, putting a privately held RNA interference drug developer in front of public-market investors at a moment when biotech listings remain selective. The company, whose backers include Fidelity, said the offering is intended to secure additional funding for its programs, which are designed to treat disease by silencing the proteins that drive it. The filing was reported on Sept. 24 by Bloomberg Industries. As is standard at this stage, the number of shares to be sold and the price range have not been set; those terms typically arrive in a later amendment, once the company has tested investor appetite during the roadshow. What RNA interference actually does. RNA interference, usually shortened to RNAi, is a way of switching off a gene before its instructions ever become a protein. Conventional small-molecule drugs and antibodies generally act on a protein after it has been made - they block it, bind it, or clear it. RNAi intervenes one step earlier, degrading the messenger RNA that carries the genetic instruction, so the problem protein is never produced in quantity in the first place. That mechanism carries two commercial consequences that matter to anyone reading an S-1. The first is durability: because the intervention works upstream, RNAi medicines have often been dosed far less frequently than daily pills, which changes the adherence profile and the way payers evaluate them. The second is targeting. Silencing a gene is only useful if the silencing agent reaches the right tissue, and delivery - getting the molecule into the liver, or beyond it - has been the discipline's central engineering problem for two decades. City Therapeutics sits in that lineage. The company describes its work as treating disease by silencing disease-related proteins, which is the defining claim of the RNAi field rather than a departure from it. What distinguishes platform companies in this space is usually the chemistry and the delivery, not the concept. Why the Fidelity name carries weight in a prospectus. Fidelity's presence on the shareholder register is more than a line item. Crossover investors - large asset managers that write private checks into late-stage rounds with a public listing in view - serve a specific function in biotech. Their participation before an IPO signals that a public-market institution has already done diligence on the science and the pipeline, and it often means part of the book is effectively pre-committed when the deal prices. For a company without product revenue, that matters enormously. Clinical-stage biotechs are priced on the credibility of the pipeline and the length of the cash runway, not on multiples of earnings. A well-known crossover holder reduces the burden on the syndicate to find every dollar of demand from scratch, and it gives smaller institutions a reason to follow. It does not, however, remove the risk. Crossover backing has preceded both strong debuts and broken ones. Investors reading the eventual pricing terms will still want to know how much of the round is new money versus insider participation, and how many quarters of operating expense the proceeds actually cover. The backdrop: a calm tape, a choosy IPO window. The filing lands in a market that has been steady rather than exuberant. At the most recent close, on Sept. 24, 2026, the S&P 500 tracker (NYSEARCA: SPY) finished at $767.18, down 0.08% on the day from a prior close of $767.81, having traded between $763.25 and $768.95. The Nasdaq 100 fund (NASDAQ: QQQ) closed at $741.10, essentially flat at -0.01%, with a day range of $734.62 to $742.66. The Dow 30 tracker (NYSEARCA: DIA) was the weakest of the three, closing at $512.68, a decline of 0.32%. The Dow 30 tracker (NYSEARCA: DIA) was the weakest of the three, closing at $512. That is a benign but unremarkable tape - no volatility shock to close the window, no melt-up to force it wide open. For issuers, that combination usually produces a two-tier outcome: deals with a differentiated story and anchor demand get done, while companies offering a generic platform pitch either price at the bottom of the range or postpone. Biotech in particular has been a buyer's market for several years, with public investors demanding clearer clinical evidence and shorter paths to data than they did during the last boom. A company filing now is implicitly arguing that its programs are far enough along, or its platform distinctive enough, to clear that higher bar. The disclosures that will decide how this prices. Until the amended filing carries a share count and a price range, the valuation question is unanswerable. But the items that will drive it are predictable, and they are the ones to read first when the full prospectus becomes public: * Pipeline stage. Whether the lead program is in the clinic, and if so in which phase, is the single biggest determinant of how a development-stage biotech is valued. * Cash runway. Net proceeds measured against quarterly operating burn, and whether that runway extends past the next meaningful data readout or stops short of it. * Delivery claims. Whether the company's silencing approach reaches tissues beyond the liver, which historically has separated the broad platforms from the narrow ones. * Ownership after the offering. How much of the company Fidelity and other pre-IPO holders retain, and whether any of them have indicated interest in the deal itself. * Partnerships. Any existing collaboration with a larger pharmaceutical company, which brings non-dilutive funding and third-party validation of the chemistry. What a successful debut would signal beyond one company. A priced deal with a firm aftermarket would be read across the sector as evidence that crossover-backed, platform-stage biotechs can still reach the public market on acceptable terms. That would matter to the queue of private RNAi and genetic-medicine companies that have been financing through extended private rounds while waiting for conditions to improve, and to the venture funds holding those positions, which need exits to return capital. A downsized or postponed offering would carry the opposite message: that public investors remain willing to fund clinical data, but not the promise of a platform. Either way, the terms in City Therapeutics' next filing amendment will be read closely by people who have no intention of buying the stock. For now, the concrete facts are narrow - a filing, a backer, a mechanism, and a stated purpose of raising more money. Everything that determines whether this is a landmark or a footnote is still to be disclosed. Key facts. * Filing: City Therapeutics Inc. filed for a U.S. IPO, reported Sept. 24, 2026 * Notable backer: Fidelity * Technology: RNA interference - silencing disease-related proteins before they are made * Market backdrop: S&P 500 (SPY) closed at $767.18, -0.08%, as of Sept. 24, 2026, 20:00 GMT Frequently asked questions. What did City Therapeutics announce? City Therapeutics Inc. filed for an initial public offering in the United States, as reported on Sept. 24, 2026. The company develops RNA interference medicines that treat disease by silencing disease-related proteins, and said the offering is intended to secure additional funding for that work. Share count and price range were not part of the initial filing. How does RNA interference work? RNA interference, or RNAi, switches off a gene before its instructions become a protein. Instead of blocking a harmful protein after it exists, an RNAi drug degrades the messenger RNA carrying the genetic instruction, so the protein is never produced in quantity. The main engineering challenge in the field has been delivering these molecules to the correct tissue. How much is City Therapeutics raising and at what valuation? Neither figure has been disclosed. An initial IPO filing typically omits the number of shares offered and the price range; those terms are added in a later amendment once the company and its underwriters have gauged investor demand during the roadshow. Until then, no valuation can be reliably calculated from public information. Why does Fidelity's involvement matter? Fidelity is a crossover investor - a large public-market asset manager that also writes private checks into late-stage rounds ahead of a listing. Its presence signals that an institution with public-market scale has already assessed the science, and it often means part of the IPO book is effectively pre-committed. It does not eliminate the risk of a weak debut. What were markets doing when the filing emerged? Trading was quiet. At the Sept. 24, 2026 close, the S&P 500 tracker SPY finished at $767.18, down 0.08%. The Nasdaq 100 fund QQQ closed at $741.10, down 0.01%, and the Dow 30 tracker DIA closed at $512.68, down 0.32%. That is a calm tape rather than a risk-on rally. What should investors watch next in the filing? The key disclosures are the stage of the lead clinical program, the cash runway that net proceeds would fund relative to quarterly operating burn, whether the delivery technology reaches tissues beyond the liver, post-offering ownership by existing backers such as Fidelity, and any collaborations with larger pharmaceutical companies that provide non-dilutive funding.